Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3192718 | 1.00 | GPR119 (0.47) | GPR119USP30ADORA2AADORA2BADORA3 | |
| SCHEMBL3328734 | 0.84 | GPR119 (0.42) | GPR119USP30ADORA2AADORA2BADORA3 | |
| SCHEMBL3332874 | 0.83 | USP30 (0.45) | GPR119USP30HPGDSUSP2SMN1; SMN2 | |
| SCHEMBL3329651 | 0.83 | USP30 (0.45) | GPR119USP30HPGDSUSP2SMN1; SMN2 | |
| SCHEMBL3185439 | 0.83 | USP30 (0.45) | GPR119USP30HPGDSUSP2SMN1; SMN2 | |
| SCHEMBL3329274 | 0.83 | USP30 (0.45) | GPR119USP30HPGDSUSP2SMN1; SMN2 | |
| SCHEMBL4937728 | 0.83 | TP53 (0.43) | ADORA2ATP53 | |
| SCHEMBL4937735 | 0.83 | TP53 (0.43) | ADORA2ATP53 | |
| SCHEMBL16634182 | 0.83 | GPR119 (0.44) | GPR119USP30ADORA2AADORA2BADORA3 | |
| SCHEMBL16634184 | 0.83 | GPR119 (0.44) | GPR119USP30ADORA2AADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | FISH PAUL VINCENT | 2008-07-03 | — | — | US | disclosed |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | FISH PAUL VINCENT | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | OPRL1, MYLK2, TNNT2 | GPR119 920/4885USP30 4534/4885ADORA2A 1809/4885 |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | OPRL1, UGT1A1, HTR3B | GPR119 1216/4885USP30 3956/4885ADORA2A 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.